https://www.openbell.ai/ 2026-10-31T22:29:01.596Z hourly 1.0 https://www.openbell.ai/support 2026-10-31T22:29:01.596Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-31T22:29:01.596Z monthly 0.5 https://www.openbell.ai/terms 2026-10-31T22:29:01.596Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-31T22:29:01.596Z hourly 0.8 https://www.openbell.ai/news/SYN:1793484101000 2026-10-31T22:01:41.000Z daily 0.9 https://cdn.brandfetch.io/SYN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Synergia Energy Ltd Releases Audited Annual Report for Fiscal Year 2026 Synergia Energy Ltd reported a 268% increase in FY2026 revenue to A$1.08 million and a 20% reduction in adjusted operating losses to A$2.8 million. Operating cash flow improved to an inflow of A$0.86 million, compared with an outflow of A$3.9 million the prior year. Four workovers at the Cambay field added about 180 BOPD, and the company eliminated gas flaring by monetizing associated gas from three wells. Synergia also announced it will relinquish its Camelot CCS licence. https://www.openbell.ai/news/GALP:1793480508000 2026-10-31T21:01:48.000Z daily 0.9 https://cdn.brandfetch.io/GALP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Galp Reports 50% Increase in Nine-Month Net Profits Galp Energia reported a 50% increase in net profit for the nine months ended in 2026. The company attributed the growth to strength in the oil sector and rising Brent crude prices; the article provides no profit amount or stock-price impact. https://www.openbell.ai/news/ACT0:1793476924000 2026-10-31T20:02:04.000Z daily 0.9 https://cdn.brandfetch.io/ACT0/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alzchem Group AG Reports Q3 2026 Results and Updates Nitroguanidin Project Alzchem Group AG said rising material costs, depreciation and planned startup expenses for new nitroguanidin capacity in Germany weighed on third-quarter 2026 earnings, but it maintained its full-year guidance. The Specialty Chemicals segment continued to grow on demand for creatine and defense-related nitroguanidin, while Basics & Intermediates faced weak agricultural and pharmaceutical demand. Higher-than-planned investment costs for a proposed US nitroguanidin plant prompted the company to renegotiate with the US Department of Defense. https://www.openbell.ai/news/CDSL:1793460719000 2026-10-31T15:31:59.000Z daily 0.9 https://cdn.brandfetch.io/CDSL/w/400/h/400?c=1idopYfmtR7ZKg8QMud CDSL Reports 24% Increase in Q2 Net Profit CDSL reported second-quarter net profit of ₹174 crore, up 24% from ₹140 crore a year earlier, while revenue rose to ₹394 crore from ₹319 crore. About 7.5 million new demat accounts were opened during the quarter, and Assets Under Custody exceeded ₹89 lakh crore. Management attributed the results to resilient securities-market participation amid global macroeconomic volatility. https://www.openbell.ai/news/BOLT:1793451965000 2026-10-31T13:06:05.000Z daily 0.9 https://cdn.brandfetch.io/BOLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bolt Biotherapeutics Completes Merger with Prana Therapies Bolt Biotherapeutics completed its acquisition of Prana Therapies through a sign-and-close reverse merger, alongside a $120 million financing. On a fully diluted basis, Prana equity holders own 51.7% of the combined company, private placement investors 41.4%, and Bolt equity holders 6.9%. Bolt is refocusing its pipeline and expects to move two additional undisclosed programs toward IND-enabling development by the second half of 2027. https://www.openbell.ai/news/COMP:1793451929000 2026-10-31T13:05:29.000Z daily 0.9 https://cdn.brandfetch.io/COMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Uniserve Communications Corporation Announces First Quarter Fiscal 2027 Financial Results Uniserve Communications reported first-quarter fiscal 2027 revenue of $2.95 million for the period ended August 31, 2026, up from $2.122 million a year earlier. Its net loss widened to $1.068 million from $264,000. The company said it is pursuing operational efficiencies, recurring-revenue growth, and improved customer value to strengthen operating results in fiscal 2027. https://www.openbell.ai/news/INO:1793451893000 2026-10-31T13:04:53.000Z daily 0.9 https://cdn.brandfetch.io/INO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Inovio Receives FDA Accelerated Approval for VOCERYQ to Treat Recurrent Respiratory Papillomatosis Inovio Pharmaceuticals said the FDA granted accelerated approval to VOCERYQ, formerly INO-3107, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis that targets HPV-6 and HPV-11 and is intended to reduce surgery frequency. It is the first plasmid DNA-based immunotherapy approved in the United States and, according to Inovio, validates its CELLECTRA delivery platform. The company expects to begin taking orders and shipping in about 60 days, with a full commercial launch anticipated in the first quarter of 2027. Approval requires Inovio to conduct a post-marketing confirmatory study. https://www.openbell.ai/news/KDK:1793451871000 2026-10-31T13:04:31.000Z daily 0.9 https://cdn.brandfetch.io/KDK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Kodiak AI Reaches 99% Autonomy Readiness Measure, On Track for Year-End Driverless Launch Kodiak AI reported that its Autonomy Readiness Measure for long-haul driverless operations reached 99%, advancing its goal of launching driverless commercial service by the end of 2026. As of the end of the second quarter of 2026, its technology was deployed in 35 driverless trucks operated by customer Atlas Energy Solutions, building on Kodiak’s Permian Basin experience. The company is pursuing commercialization of its hardware-agnostic virtual driver technology through its Driver-as-a-Service model; the article did not report financial results or a stock-price move.